BlackRock
VTGN icon

BlackRock’s VistaGen Therapeutics VTGN Stock Holding History

BlackRock’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78.1K Sell
345,432
-103,075
-23% -$62.2K ﹤0.01% 5063
2026
Q1 		$256K Buy
448,507
+25,748
+6% +$15.6K ﹤0.01% 4702
2025
Q4 		$280K Sell
422,759
-369
-0.1% -$1.33K ﹤0.01% 4632
2025
Q3 		$1.5M Buy
423,128
+6,239
+1% +$18.6K ﹤0.01% 4183
2025
Q2 		$834K Buy
416,889
+551
+0.1% +$1.25K ﹤0.01% 4311
2025
Q1 		$1.04M Buy
416,338
+4,785
+1% +$13.5K ﹤0.01% 4174
2024
Q4 		$1.21M Sell
411,553
-576
-0.1% -$1.62K ﹤0.01% 4180
2024
Q3 		$1.24M Buy
412,129
+9,382
+2% +$32K ﹤0.01% 4131
2024
Q2 		$1.4M Buy
402,747
+54,309
+16% +$235K ﹤0.01% 4078
2024
Q1 		$1.84M Buy
348,438
+1,755
+0.5% +$8.44K ﹤0.01% 4025
2023
Q4 		$1.78M Buy
346,683
+258,637
+294% +$979K ﹤0.01% 4081
2023
Q3 		$461K Sell
88,046
-16,960
-16% -$75.3K ﹤0.01% 4447
2023
Q2 		$196K Sell
105,006
-335,076
-76% -$1.17M ﹤0.01% 4744
2023
Q1 		$1.65M Buy
440,082
+31,150
+8% +$163K ﹤0.01% 4135
2022
Q4 		$1.26M Buy
408,932
+19,113
+5% +$71.9K ﹤0.01% 4334
2022
Q3 		$1.78M Sell
389,819
-716
-0.2% -$7.1K ﹤0.01% 4246
2022
Q2 		$10.3M Sell
390,535
-546
-0.1% -$19.3K ﹤0.01% 3492
2022
Q1 		$14.5M Sell
391,081
-5,392
-1% -$235K ﹤0.01% 3371
2021
Q4 		$23.2M Buy
396,473
+4,857
+1% +$316K ﹤0.01% 3181
2021
Q3 		$32.2M Buy
391,616
+3,282
+0.8% +$285K ﹤0.01% 2958
2021
Q2 		$36.7M Buy
388,334
+299,881
+339% +$22.2M ﹤0.01% 2900
2021
Q1 		$5.65M Buy
88,453
+87,312
+7,652% +$5.83M ﹤0.01% 3887
2020
Q4 		$66K Buy
1,141
+43
+4% +$1.1K ﹤0.01% 4638
2020
Q3 		$23K Hold
1,098
– – ﹤0.01% 4702
2020
Q2 		$17K Sell
1,098
-51
-4% -$698 ﹤0.01% 4724
2020
Q1 		$15K Buy
1,149
+95
+9% +$1.74K ﹤0.01% 4660
2019
Q4 		$22K Buy
+1,054
New +$26.6K ﹤0.01% 4643

Other funds holding VTGN

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
CWS
Confluence Wealth Services Mcmurray, Pennsylvania $3.5B AUM 22.08% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
RS
R Squared Central, Hong Kong $190M AUM 25.89% 1-Year Est. Return

BlackRock's VTGN Position: Q2 2026 in Review

BlackRock reduced its VistaGen Therapeutics (VTGN) stake by 23% in Q2 2026, selling an estimated $62.2K and leaving 345,432 shares worth $78.1K. The position accounts for ﹤0.01% of the portfolio, ranked #5063.

BlackRock first reported a position in VTGN in Q4 2019 and has held it in 27 quarters since. The position peaked at $36.7M in Q2 2021. 25 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

  • BlackRock held 345,432 shares of VistaGen Therapeutics worth $78.1K as of Q2 2026.
  • BlackRock sold 103,075 VistaGen Therapeutics shares in Q2 2026, an estimated $62.2K.
  • VistaGen Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5063 holding.
  • BlackRock first reported a position in VistaGen Therapeutics in Q4 2019 and has held it in 27 quarters since.
  • BlackRock's VistaGen Therapeutics position peaked at $36.7M in Q2 2021.
  • 25 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.